AVITA Medical Inc
Company Profile
Business description
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
Contact
28159 Avenue Stanford
Suite 220, Valencia
Los AngelesCA91355
USAT: +1 833 462-8482
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2024
Employees
207
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,450.90 | 64.30 | -0.76% |
CAC 40 | 7,236.85 | 9.87 | 0.14% |
DAX 40 | 19,066.63 | 32.99 | 0.17% |
Dow JONES (US) | 43,910.98 | 382.15 | -0.86% |
FTSE 100 | 8,031.83 | 6.06 | 0.08% |
HKSE | 19,823.45 | 23.43 | -0.12% |
NASDAQ | 19,281.40 | 17.36 | -0.09% |
Nikkei 225 | 38,721.66 | 654.43 | -1.66% |
NZX 50 Index | 12,674.49 | 74.87 | -0.59% |
S&P 500 | 5,983.99 | 17.36 | -0.29% |
S&P/ASX 200 | 8,193.40 | 62.20 | -0.75% |
SSE Composite Index | 3,439.28 | 17.31 | 0.51% |